The loss of Aurinia Pharmaceuticals under IFRS for 9 months of 2020 amounted to $80.124 million, an increase of 69.2% compared to $47.366 million in the previous year. Revenue decreased 3.3 times to $88,000 against $289,000 a year earlier.